Skip to main content Skip to search Skip to main navigation
News: Cannabis

UN: Cannabis removed from Schedule IV of most dangerous drugs

As announced by the UN Commission on 2 December 2020, cannabis was removed from Schedule IV of the 1961 Single Convention on Narcotic Drugs following WHO's recommendation.

The 53 members of the Commission on Narcotic Drugs (CND), the UN's central body for drug policy decisions, voted conceivably close with 27 in favor, 25 against and one abstention. Cannabis was placed in Schedule IV for 59 years, along with heroin and carfentanil. Schedule IV substances are considered "particularly harmful and of extremely limited medical or therapeutic value". Now cannabis has been moved to Schedule I, where methadone and cocaine are listed, as well. However, its use for non-medical and non-scientific purposes is still illegal.  

Background  

The WHO had already submitted six recommendations on cannabis and related substances in January 2019. However, many countries asked for more time to deal with the matter.   

Current status  

Currently, more than 50 countries have adopted programs on medical cannabis. Canada, Uruguay and 15 US states have legalized its recreational use. In Mexico and Luxembourg this is already discussed. 


Source:

UN: UN commission reclassifies cannabis, yet still considered harmful 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

Question of the Week | GMP-Verlag

What are the Benefits and Limitations of Passive Temperature-Controlled Containers for Drug Transport?

Here's the answer:
Read more
Outsourced Activities in the GDP Environment Part II: Contractual Agreements

Outsourced Activities in the GDP Environment Part II: Contractual Agreements

When outsourcing GDP activities, there is a need for concrete delimitation of responsibilities between a client and a contractor. Read more about the goals and the contents of a quality agreement in the following excerpt from GMP:KnowHow Pharmalogistics (GDP).

Read more
FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

The FDA has updated its recommendations on Acceptable Intake (AI) limits for nitrosamine impurities. Under certain conditions, the Agency now accepts a Less-Than-Lifetime (LTL) adjustment of AI limits for medicinal products that are not intended for lifetime use. This also represents an alignment with the LTL concept of ICH M7(R2).
Read more
Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

As of 15 November 2026, active substances must be registered in the EMA's Substance Management Services (SMS) database before Swissmedic can include them in establishment licences and GMP certificates for active substance manufacturers. The new requirement results from modifications to the EudraGMDP database.
Read more
News: EMA

EMA: New Q&As for Biological Medicinal Products

The EMA has added a new section to its Q&As on biological medicinal products addressing medicinal products containing secretomes or extracellular vesicles (EVs) obtained from human or animal cells.
Read more
News: Europe

EU: Council Adopts the Pharmaceutical Package

On 28 September 2026, the Council of the European Union adopted the EU pharmaceutical package, marking another important step in the legislative process for the comprehensive reform of EU pharmaceutical legislation.
Read more
Previous
Next